oncotherapeutics.com

Oncotherapeutics

Full Service Contract Research Organization (CRO). Oncotherapeutics offers a comprehensive service portfolio that supports preclinical studies and clinical trials from phase I to IV. We strive to provide high quality deliverables and our clients, from small start-up biotech (16-50 employees) to large biotechnology and pharmaceuticals (10,000 employees), enjoy the benefits of our proactive, specialized approach. MEDNET Solutions Welcomes Oncotherapeutics to the MEDNET Partner Program. Website Design by AI...

http://www.oncotherapeutics.com/

OVERVIEW OF oncotherapeutics.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

20

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR ONCOTHERAPEUTICS.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

December

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Friday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.8 out of 5 with 10 reviews

5 star

1

4 star

6

3 star

3

2 star

0

1 star

0

Hey there! Start your review of oncotherapeutics.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

1.5 seconds

FAVICON PREVIEW

16x16
32x32
64x64
128x128
160x160
192x192

CONTACTS AT ONCOTHERAPEUTICS.COM

Oncotherapeutics

Nuhad Barakat

9201 w. su●●●●●●●●●●, ste. 317

West ●●●●●ywood , CA, 90069

US

1.31●●●●1200

1.31●●●●1121

nb●●●●●●@imbcr.org

View this contact

Oncotherapeutics

Nuhad Barakat

9201 w. su●●●●●●●●●●, ste. 317

West ●●●●●ywood , CA, 90069

US

1.31●●●●1200

1.31●●●●1121

nb●●●●●●@imbcr.org

View this contact

Neutrino Networks

Neutrino Networks

9911 W P●●●●●●●● Ste 530

Los ●●●●eles , CA, 90035

US

1.31●●●●4435

su●●●●●@goneutrino.com

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: 2002 May 28
UPDATED: 2014 May 13
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

DOMAIN AGE

22

YEARS
0

MONTHS
26

DAYS

NAME SERVERS

1: ns1.dreamhost.com
2: ns2.dreamhost.com
3: ns3.dreamhost.com

REGISTRAR

TUCOWS DOMAINS INC.

WHOIS : whois.tucows.com

REFERRED : http://domainhelp.opensrs.net

CONTENT

PAGES IN
THIS WEBSITE

20

SSL

EXTERNAL LINKS

20

SITE IP

208.113.160.132

LOAD TIME

1.5 sec

SCORE

6.2

PAGE TITLE

Oncotherapeutics | oncotherapeutics.com Reviews

<META> DESCRIPTION

Full Service Contract Research Organization (CRO). Oncotherapeutics offers a comprehensive service portfolio that supports preclinical studies and clinical trials from phase I to IV. We strive to provide high quality deliverables and our clients, from small start-up biotech (16-50 employees) to large biotechnology and pharmaceuticals (10,000 employees), enjoy the benefits of our proactive, specialized approach. MEDNET Solutions Welcomes Oncotherapeutics to the MEDNET Partner Program. Website Design by AI...

<META> KEYWORDS

1 oncotherapeutics

2 about us

3 clinical trials

4 publications

5 links

6 become an investigator

7 recent posts

8 categories

9 abstracts

10 press release

CONTENT

Page content here

KEYWORDS ON PAGE

SERVER

Apache

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Oncotherapeutics | oncotherapeutics.com Reviews

https://oncotherapeutics.com

Full Service Contract Research Organization (CRO). Oncotherapeutics offers a comprehensive service portfolio that supports preclinical studies and clinical trials from phase I to IV. We strive to provide high quality deliverables and our clients, from small start-up biotech (16-50 employees) to large biotechnology and pharmaceuticals (10,000 employees), enjoy the benefits of our proactive, specialized approach. MEDNET Solutions Welcomes Oncotherapeutics to the MEDNET Partner Program. Website Design by AI...

INTERNAL PAGES

oncotherapeutics.com

1

Clinical Trial Monitoring | Oncotherapeutics

http://www.oncotherapeutics.com/services-2/clinical-development/clinical-trial-monitoring

Full Service Contract Research Organization (CRO). Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. To accommodate our client’s and study needs, we offer on-site visits or remote monitoring. Our highly qualified clinical research associates (CRAs) ensure the highest quality review of data and effective interaction with study sites. Our clinical monitoring services include:.

2

Regulatory Affairs | Oncotherapeutics

http://www.oncotherapeutics.com/services-2/clinical-development/regulatory-affairs

Full Service Contract Research Organization (CRO). Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Oncotherapeutics provides comprehensive regulatory services, assisting in the preparation and publication of paper-based and electronic submissions to the FDA and IRBs. Oncotherapeutics presents at ASH 2014. Oncotherapeutics presents at ASCO 2014. Subscribe to our Mailinglist.

3

Become an Investigator | Oncotherapeutics

http://www.oncotherapeutics.com/become-an-investigator

Full Service Contract Research Organization (CRO). Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. A vital component of our clinical research team is our nation-wide network of investigators and trusted sites. Oncotherapeutics. To enlist experienced investigators to run clinical trials treating a variety of indications. Oncotherapeutics presents at ASH 2014. MEDNET Solutio...

4

Quality Assurance and Compliance | Oncotherapeutics

http://www.oncotherapeutics.com/services-2/clinical-development/quality-assurance-and-compliance

Full Service Contract Research Organization (CRO). Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Quality Assurance and Compliance. We have a comprehensive internal quality assurance program, which ensures that Oncotherapeutics personnel comply with FDA requirements and ICH/GCP guidelines and conduct trial activities in accordance with the study protocol. A Phase 1/2 Stud...

5

IXRS Services | Oncotherapeutics

http://www.oncotherapeutics.com/services-2/clinical-development/ixrs-services

Full Service Contract Research Organization (CRO). Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Please submit inquiries with your specific needs. Oncotherapeutics presents at ASH 2014. Oncotherapeutics guest blog post goes live today on the MedNet website. Oncotherapeutics presents at ASCO 2014. MEDNET Solutions Welcomes Oncotherapeutics to the MEDNET Partner Program.

UPGRADE TO PREMIUM TO VIEW 15 MORE

TOTAL PAGES IN THIS WEBSITE

20

LINKS TO THIS WEBSITE

berensononcology.com

James R. Berenson, MD, Inc. | Category Archive | Multiple Myeloma

http://www.berensononcology.com/category/multiple-myeloma

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. RSS feed for this section. Targeted Myeloma Treatments Bring Hope for Fewer Side Effects and Curative Therapy. January 21, 2014. Experts Disagree on Role of Transplant in Myeloma. October 4, 2013. Multiple Myeloma Survival Increased Significantly The Past 15 Years, But Unevenly Across Ethnic And Age Groups. September 3, 2013. Posted By Navneet Ramesh and Maike Haehle on the Myeloma Beacon on Aug 31, 2013 2:01 Researchers recently reported updated survival...

berensononcology.com

James R. Berenson, MD, Inc. | Maureen V

http://www.berensononcology.com/testimonials/patient-testimonials/maureen-v

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. The Great Wall of China. Actress and Adult Eduction Teacher (retired). Here I am climbing the Great Wall of China. Two months before, it had been questionable whether I would be able to go on my long-planned journey. Chemotherapy had not been as successful in treating my multiple myeloma as we had hoped. Then, Dr. Berenson put me on a course of Revlimid and Medrol, and, as you can see, I have been doing extremely well! American Society of Clinical Oncology.

berensononcology.com

James R. Berenson, MD, Inc. | Category Archive | articles

http://www.berensononcology.com/category/articles

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. RSS feed for this section. Counterpoints: Do Patients With Multiple Myeloma Need Maintenance Treatment? April 13, 2015. In this month’s […]. Talking About Myeloma with Loved Ones. February 6, 2015. Do you feel the Love? The New Year is here. Perhaps you have been newly diagnosed? Whether a Myeloma warrior, or new to the world of MM, talking about the disease with loved ones can be difficult, at best. What is Multiple Myeloma anyway? April 10, 2014. Chief ...

berensononcology.com

James R. Berenson, MD, Inc. | Category Archive | Movie Premier

http://www.berensononcology.com/category/movie-premier

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. RSS feed for this section. Love Is All You Need – Movie Premiere Benefiting the Institute for Myeloma & Bone Cancer Research. March 28, 2013. James R. Berenson, MD. President and CEO - James R. Berenson, MD, Inc. Medical and Scientific Director - Institute for Myeloma. Bone Cancer Research (IMBCR). Chief Executive Officer - Oncotherapeutics. An Interview With Patient Advocate Debra Berenson. May 24, 2016. February 22, 2016. July 17, 2015. May 21, 2015.

berensononcology.com

James R. Berenson, MD, Inc. | Category Archive | headline

http://www.berensononcology.com/category/headline

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. RSS feed for this section. IMBCR – KTLA 5 News – Segment 3. March 6, 2014. Tom Brokaw Bravely Facing Cancer Diagnosis. February 12, 2014. James R. Berenson, MD. President and CEO - James R. Berenson, MD, Inc. Medical and Scientific Director - Institute for Myeloma. Bone Cancer Research (IMBCR). Chief Executive Officer - Oncotherapeutics. An Interview With Patient Advocate Debra Berenson. May 24, 2016. February 22, 2016. July 17, 2015. May 21, 2015. Unders...

berensononcology.com

James R. Berenson, MD, Inc. | Multiple Myeloma Q&A

http://www.berensononcology.com/multiple-myeloma

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. Multiple Myeloma Q&A. How do you know if you have multiple myeloma? How do the doctors decide what treatment to use for your myeloma? What are the types of therapies that are used to treat myeloma? How do you know if the treatment is working? How do I know if the treatment is working? At what point do you need to change your treatment? What are the specific drugs used to treat myeloma? James R. Berenson, MD. Bone Cancer Research (IMBCR). May 24, 2016.

berensononcology.com

James R. Berenson, MD, Inc. | Category Archive | Papers

http://www.berensononcology.com/category/papers

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. RSS feed for this section. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. February 19, 2013. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. November 19, 2012. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. March 19, 2011.

berensononcology.com

James R. Berenson, MD, Inc. | Category Archive | Press Releases

http://www.berensononcology.com/category/press-releases

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. RSS feed for this section. An Interview With Patient Advocate Debra Berenson. May 24, 2016. Interview with Debra Berenson, myeloma patient advocate, wife of myeloma expert Dr. James Berenson, and author of the book, I HAVE WHAT? May 21, 2015. December 18, 2014. How do you know if you are getting the right drugs at the right doses for treating your myeloma? December 9, 2014. The Institute has been involved in very exciting work this year. We have ident...

berensononcology.com

James R. Berenson, MD, Inc. | Category Archive | ASCO

http://www.berensononcology.com/category/asco

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. RSS feed for this section. ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. June 23, 2014. James R. Berenson, MD. President and CEO - James R. Berenson, MD, Inc. Medical and Scientific Director - Institute for Myeloma. Bone Cancer Research (IMBCR). Chief Executive Officer - Oncotherapeutics. Novem...

berensononcology.com

James R. Berenson, MD, Inc. | Berenson Oncology

http://www.berensononcology.com/articles

Multiple Myeloma Q&A. James R. Berenson, MD, Inc. May 24, 2016. An Interview With Patient Advocate Debra Berenson. Interview with Debra Berenson, myeloma patient advocate, wife of myeloma expert Dr. James Berenson, and author of the book, I HAVE WHAT? Debra has collected stories, insights, and tools for and from patients and their families with myeloma and related diseases. The second half of the book includes information and advice from doctors and other healthcare professionals who treat […]. What: Mye...

UPGRADE TO PREMIUM TO VIEW 10 MORE

TOTAL LINKS TO THIS WEBSITE

20

OTHER SITES

oncotheater.com

Oncotheater.com

oncotheis.com

OncoTheis in vitro solutions for preclinical oncology

Solutions for preclinical oncology. Provider of cells, 3D tissues and testing services. Conferences and upcoming events. OncoTheis Bio 2018 Sat 30 Jun 2018. Live Meeting Tue 10 Jul 2018. EACR BERLIN Sun 09 Sep 2018. Meet OncoTheis @ EUSAAT Sun 23 Sep 2018. Mon 31 Dec 2018.

oncother.com

Find the best domain names to register

Register a Domain Name Who Owns This Domain? The domain name registration process for your businesses web site begins here. Register a great domain name with Verio from only $9.95 and receive a free 3 page website and email account. 1 Find Your Domain Name. 2 Choose Your Extensions. Enter up to 5 domain names. Couk ($38 for 2 years). Create the site you want with Verio hosting plan options. Verio is your strategic partner for top-tier hosting for complex websites and dedicated hosting.

oncotherapeutica.com

This site is under development

This site is under development. This page indicates the webmaster has not uploaded a website to the server. For information on how to build or upload a site, please visit your web hosting company's site.

oncotherapeutics-us.com

Oncotherapeutics

Full Service Contract Research Organization (CRO). Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Our Mission and Values. Site Recruitment and Activation. Quality Assurance and Compliance. Oncotherapeutics is a full service Contract Research Organization (CRO) with a unique focus in oncology. Our history of client satisfaction and success is the best testimony of our commitment to our clients. Oncotherapeutics presents at ASH 2014. A Phase 1/2 Study of Carfilzo...

oncotherapeutics.com

Oncotherapeutics

Full Service Contract Research Organization (CRO). Oncotherapeutics offers a comprehensive service portfolio that supports preclinical studies and clinical trials from phase I to IV. We strive to provide high quality deliverables and our clients, from small start-up biotech (16-50 employees) to large biotechnology and pharmaceuticals (10,000 employees), enjoy the benefits of our proactive, specialized approach. MEDNET Solutions Welcomes Oncotherapeutics to the MEDNET Partner Program. Website Design by AI...

oncotherapie.nl

Mihosnet - Gereserveerd domein

Your browser does not support frames.

oncotherapy.co.jp

OncoTherapy Science, Inc.

がん特異的ペプチドワクチン S-588410 第相臨床試験進捗最終患者登録に関するお知らせ. 当社連結子会社と Thermo Fisher Scientific との新規リキッドバイオプシープラットフォーム評価のための提携についてのお知らせ. オンコセラピーサイエンス OTS では、がん分子標的治療薬の開発に適した標的遺伝子を多数同定しています。血液組織などの検体中に存在しているT細胞のTCR遺伝子配列情報を、次世代シーケンサーを用いて網羅的に取得し詳細に解析する T細胞受容体 TCR 解析サービス。私たちは、より治療効果が高く、より副作用の少ないがん治療薬治療法を、一日も早くがんに苦しむ患者さんに届けること、がんとの闘いに勝つことを目指し、ジェノミックスを医療分野に先駆者としてもたらした中村祐輔教授とともに、研究開発に取り組んでいます。

oncotherapy.us

US OncoTherapy systems BioMedicine Group

oncotherapynetwork.com

Oncotherapy Network

We've noticed that you're using an ad blocker. Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker. How do I disable my ad blocker? How to disable your ad blocker for our site:. Adblock / Adblock Plus. Click on the AdBlock / AdBlock Plus icon on the top right of your browser. Click Don’t run on pages on this domain. OR Enabled on this site. Close this help box and click "It's off now". Dec 21, 2017.

oncotherapyresources.com

SD-IORT > Home

How to book SD-IORT. Information for existing users. Early stage breast cancer. Am I suitable for SD-IORT? How does SD-IORT work? Where is SD-IORT available? For the Healthcare Professional. Information on the system. Where is SD-IORT available? How to book SD-IORT. Information for existing users. Early stage breast cancer. Am I suitable for SD-IORT? How does SD-IORT work? Where is SD-IORT available? For the Healthcare Professional. Information on the system. Where is SD-IORT available? You are here: Home.